Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 …
1. 系统已在2026-04-27 16:43:49对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
N Colombo, E Zsiros, G Parma, E Rulli, A Sebastianelli…
The Lancet, 2026
thelancet.com
Background Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improves progression-free survival and overall survival compared with weekly paclitaxel, with or without bevacizumab, in participants with platinum-resistant recurrent ovarian cancer who had received one to two 2 previous systemic regimens. Methods ENGOT-ov65/KEYNOTE-B96 is a randomised, double-blind, phase 3 study …
